Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

GLAND is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 4.129000
forwardPE 23.185972
debtToEquity 3.161000
earningsGrowth 0.123000
revenueGrowth 0.058000
grossMargins 0.586090
operatingMargins 0.139610
trailingEps 47.950000
forwardEps 72.565430

Gland Pharma Limited's current ratio is 4.129, showing the company's capacity to service its short-term debt through its cash reserves and current assets. This is a positive indicator of liquidity, suggesting Gland Pharma Limited has no trouble covering its short-term financial obligations.
GLAND's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
GLAND's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting GLAND to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for GLAND
Price projections for GLAND

Gland Pharma Limited's price has consistently hovered around the lower end of analysts' projections. This pattern may reflect concerns regarding the company's ability to achieve its anticipated growth.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


Gland Pharma Limited had 3 sell transactions, while the market price was at 1928.3332926432292 per share.The period under consideration saw no sell transactions.With more buys than sells around GLAND's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


Recent analysis shows a strong buy bias for GLAND, encouraging investors to view it as a solid investment option. The positive sentiment surrounding GLAND suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.